Life sciences companies have an essential role in partnering with providers to deliver targeted communications about medication efficacy and adherence – not only where COVID-19 is well-established, but alsoin areas of emerging risk.
John Pagliuca and Prasad Dindigal
Advertisement
John Pagliuca is Vice President, Global Life Sciences, and Prasad Dindigal is Vice President, Healthcare & Life Sciences, both at EXL.
Articles by John Pagliuca and Prasad Dindigal
Advertisement
Latest Updated Articles
- How Life Sciences Companies Can Promote Greater Medication Adherence During COVID19
Published: May 8th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
2
GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate
3
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
4
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
5
